- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Immune System Diseases1000+
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Immune System Diseases1000+
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- HER2 positive
- PD-L1 positive
- EGFR positive
- KRAS positive
- PR positive
- PR negative
- ER negative
- BRAF positive
- EGFR negative
- PD-L1 negative
- p16 positive
- CD19 positive
- HLA-A positive
- IDH positive
- ALK negative
- ALK positive
- CD20 positive
- BRCA1 positive
- BRCA2 positive
- HLA positive
- MET positive
- IDH negative
- ROS1 positive
- TP53 positive
- MYC positive
- HLA negative
- MSI-H positive
- p16 negative
- FLT3 positive
- ROS1 negative
- HR positive
- NRAS positive
- BRAF negative
- PALB2 positive
- RB1 negative
- HLA-A negative
- RB1 positive
- dMMR positive
- NF1 positive
- PIK3CA positive
- HPV positive
- RET positive
- BRCA positive
- CD22 positive
- MET negative
- NTRK positive
- BCL2 positive
- RAS positive
- HPV negative
- MGMT negative
- ATM positive
- BCL6 positive
- CD30 positive
- ARID1A positive
- KRAS negative
- anti-dsDNA positive
- BCR-ABL1 positive
- KIT positive
- MMR positive
- Philadelphia chromosome positive
- ANA positive
- CFTR positive
- HRAS positive
- MGMT positive
- CCND1 positive
- MLH1 positive
- MSH6 positive
- NPM1 positive
- PD-1 positive
- RAS negative
- ctDNA positive
- CD123 positive
- CD33 positive
- FGFR2 positive
- MSH2 positive
- PMS2 positive
- RAD51 positive
- BRIP1 positive
- CHEK2 positive
- HBV DNA negative
- HbSS positive
- KMT2A positive
- NTRK1 positive
- PTEN positive
- RET negative
- HBsAg positive
- MSI positive
- MTAP positive
- PD-1 negative
- anti-Sm positive
- AR positive
- ASXL1 positive
- FGFR positive
- FGFR3 positive
- HBV DNA positive
- HBsAg negative
- MMR negative
- MSI negative
- MSS positive
- NF2 positive
- NRAS negative
- RUNX1 positive
- STK11 positive
- TP53 negative
- t(11;14) positive
- BRCA negative
- CD3 positive
- CDK4 positive
- FANCA positive
- GPC3 positive
- HPV16 positive
- MSI-H negative
- MSS negative
- NTRK negative
- RAD51C positive
- p53 positive
- BCR-ABL positive
- CD4 positive
- CLDN18.2 positive
- FLT3 negative
- HR negative
- JAK2 positive
- PDGFRA positive
- RAD51D positive
- RAF positive
- T790M positive
- ZnT8 positive
- dMMR negative
- ABCA4 positive
- BAP1 positive
- BARD1 positive
- BRCA1 negative
- BRCA2 negative
- CCNE1 positive
- CD19 negative
- CD5 positive
- CD70 positive
- CDK12 positive
- DLL3 positive
- DMD positive
- Del(17p) positive
- EBV positive
- EPCAM positive
- EZH2 positive
- GATA2 positive
- GRN positive
- HBcAb negative
- IA-2 positive
- Ki-67 positive
- MECP2 positive
- NF1 negative
- PTEN negative
- PTPN11 positive
- Ph positive
- RAD54L positive
- RF positive
- SMARCA4 positive
- SMN1 positive
- TERT positive
- TROP2 positive
- t(14;16) positive
- t(4;14) positive
- t(9;22) positive
- \-7 positive
- AKT1 positive
- APC positive
- APOL1 positive
- ApoE ε4 positive
- B7-H3 positive
- CD38 positive
- CDK6 positive
- CEA positive
- CHEK1 positive
- CLDN6 positive
- COL7A1 positive
- Complex karyotype positive
- DMPK positive
- DNMT3A positive
- FANCL positive
- FMR1 positive
- FRα positive
- H3K27M positive
- HBB positive
- HBcAb positive
- HRD positive
- HbSC positive
- HbSβ0-thalassemia positive
- MDM2 positive
- MLH1 negative
- MLL rearrangement positive
- MSH2 negative
- MSH6 negative
- NBN positive
- PMS2 negative
- Philadelphia chromosome negative
- SF3B1 positive
- TMB positive
- TROP2 negative
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1927nm Fractional Thulium Laser Treatment
- 30-day washout period after Erythropoietin-Stimulating Agent or IV Iron
- Activity Modification
- Adalimumab
- Adjuvant Chemotherapy without Concurrent Biologic/Targeted Therapy
- Adjuvant Therapy (except reconstruction)
- Adverse Event from Previous Treatment (Excluding Alopecia, Cutaneous Toxicity, Peripheral Neuropathy, Fatigue Grade ≤ 2)
- Alectinib for ALK
- Allogeneic Hematopoietic Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplant using Bone Marrow, Peripheral Blood, or Umbilical Cord Stem Cells
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
11256 trials
1
2
3
…50